This bill amends existing Washington law (RCW 70.14.100 and RCW 70.14.110) to change how the state selects and reviews health technologies for inclusion in participating agencies’ health care programs. It is a procedural and administrative change, not a criminal or penalty provision. The administrator, working with participating agencies and the health technology clinical committee, selects technologies for review and must give priority to technologies with established or recommended patient access under federal Medicare decisions or in nationally recognized expert treatment guidelines. The committee may also review technologies petitioned by interested parties. The statute requires contracting for a systematic, evidence-based assessment (with an evidence-based practice center or similar entity) of safety, efficacy, and cost-effectiveness, with assessments initiated no sooner than 30 days after internet notice. Selection and rereview criteria are specified, including concerns about safety, efficacy, cost-effectiveness, high state expenditures, availability of evidence, and special consideration of clinical trial evidence for life-threatening or rare diseases. The committee must determine any conditions for coverage and the medical necessity criteria agencies should use. The law sets process requirements for openness, public comment, potential ad hoc advisory groups (whose members have civil liability immunity for official acts in good faith and must meet conflict-of-interest terms), and gives primacy to Medicare and expert guideline consistency unless substantial contrary evidence exists in the assessment. The bill adds procedural deadlines: the health care authority must publish receipt of submissions within 30 days; the committee must complete reviews and notify submitters within 180 days of submission and must provide a written substantive rationale within that 180 days for adverse determinations; technologies must be reconsidered at least every 18 months or sooner if new evidence could change a determination. The text supplied does not define key actors (for example, “administrator,” “committee,” or “participating agencies”), does not include the referenced posting provision in RCW 70.14.130, and does not clarify current applicability of historical selection limits mentioned in the text.

If enacted, the agency in charge would systematically pick health technologies for evidence reviews with priority for items already covered or recommended by Medicare or major expert guidelines, and would require formal, contracted assessments that weigh safety, outcomes, cost, and impacts on specific populations. Reviews must include public comment, permit petitions from interested parties, use ad hoc advisory groups when needed, aim to follow Medicare and expert guidance unless strong contrary evidence is found, and must be completed and posted on timelines (receipt posted within 30 days and determinations, including written reasons for adverse findings, within 180 days), with any determination rereviewed at least every 18 months or sooner if new evidence emerges. The practical effects will fall heaviest on the health care authority/administrator and participating state agencies, which will face new contracting and analytic work and likely added costs to commission evidence-based assessments and to gather safety, outcome, and cost data; evidence centers doing the reviews would see new work. Providers, patients, and manufacturers of reviewed technologies may see more predictable, evidence-based coverage criteria but also more frequent changes in whether and how treatments are covered, and decisions are likely to track Medicare unless strong new evidence supports a different result. Key implementation details are unclear from the text provided, including the exact identities and roles of the “administrator,” “committee,” and “participating agencies,” and procedures for posting notices and submitting petitions.